Management of Dyspnea in Advanced Cancer: ASCO Guideline. 22nd February 2021 To provide guidance on the clinical management of dyspnea in adult patients […]
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy. 22nd February 2021 We proposed that a test for sensitivity to the adjuvant endocrine therapy […]
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. 22nd February 2021 Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of […]
FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma. 21st February 2021 CLDN18.2 is contained within normal gastric mucosa epithelial tight junctions; upon malignant […]
Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy. 20th February 2021 Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 […]
Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. 18th February 2021 Although the prognosis of patients with thin primary cutaneous melanomas (T1, ≤ […]
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). 18th February 2021 TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very […]
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. 16th February 2021 To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy […]
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. 15th February 2021 Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free […]
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial. 15th February 2021 Whether extended lymphadenectomy for right colon cancer leads to increased perioperative complications […]
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. 14th February 2021 Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably […]
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. 13th February 2021 Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal […]
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. 12th February 2021 Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy […]
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). 12th February 2021 Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an […]
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. 12th February 2021 To prospectively validate the use of a simplified geriatric assessment (sGA) at […]
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. 10th February 2021 The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated […]
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. 9th February 2021 It remains controversial whether primary tumor resection (PTR) before chemotherapy improves survival […]
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. 9th February 2021 Genetic testing is important for breast and ovarian cancer risk reduction and […]
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. 8th February 2021 Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) […]
CanDirect: Effectiveness of a Telephone-Supported Depression Self-Care Intervention for Cancer Survivors. 8th February 2021 Depression in post-treatment cancer survivors is common and can impair quality of […]
Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study. 8th February 2021 Screening for breast cancer and cervical cancer in the newly independent states […]
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). 8th February 2021 SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant […]
Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges. 6th February 2021 Liquid biopsy in cancer has gained momentum in clinical research and is […]
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. 5th February 2021 In this Policy Review, the Bone Working Group of the International Myeloma […]
Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study. 4th February 2021 First-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a […]
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. 4th February 2021 Resistance to standard chemotherapy in metastatic triple-negative breast cancer (mTNBC) is associated […]
Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. 4th February 2021 Patients with childhood, adolescent, and young adult cancer who will be treated […]
Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. 4th February 2021 Male patients with childhood, adolescent, and young adult cancer are at an […]
Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. 4th February 2021 Female patients with childhood, adolescent, and young adult cancer are at increased […]
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. 4th February 2021 Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian […]
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. 4th February 2021 Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: […]
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. 4th February 2021 Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care […]
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. 4th February 2021 The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed […]
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. 4th February 2021 APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant […]
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. 4th February 2021 Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes […]
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. 4th February 2021 Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and […]
Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. 3rd February 2021 To assess the risk of meningioma associated with use of high dose […]
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. 2nd February 2021 Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in […]
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. 2nd February 2021 Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated […]
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? 2nd February 2021 Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment […]
A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer. 31st January 2021 Type 2 diabetes (T2D) has been associated with increased breast cancer risk, […]
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. 27th January 2021 BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ […]
Burkitt Lymphoma International Prognostic Index. 27th January 2021 Burkitt lymphoma (BL) has unique biology and clinical course but lacks a […]
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. 27th January 2021 We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare […]
Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline. 27th January 2021 The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on […]
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. 26th January 2021 We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic […]
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. 26th January 2021 Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, […]
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). 25th January 2021 As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma […]
Incidence and Predictors of Mental Health Outcomes Among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study Using the IMPACT Cohort. 25th January 2021 Risk and predictors of long-term mental health outcomes in survivors of adolescent […]
Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis. 24th January 2021 Estimating a population-level benchmark rate for use of surgery in the management […]
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. 24th January 2021 The growing demand for cancer surgery has placed a global strain on […]
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. 21st January 2021 The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been […]
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. 21st January 2021 First-line nivolumab plus ipilimumab has shown improved overall survival in patients with […]
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. 20th January 2021 This study investigates whether focal boosting of the macroscopic visible tumor with […]
A Population-Based Study of Genes Previously Implicated in Breast Cancer. 20th January 2021 Population-based estimates of the risk of breast cancer associated with germline pathogenic […]
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. 18th January 2021 Aberrant activation of RET is a critical driver of growth and proliferation […]
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial. 16th January 2021 This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) […]
Risk-Based Selection of Individuals for Oral Cancer Screening. 15th January 2021 We evaluated proof of principle for resource-efficient, risk-based screening through reanalysis of […]
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. 15th January 2021 Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of […]
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. 15th January 2021 Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission […]
